Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Clinical trial NCT05546866 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05546866
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-09
- Primary completion
- 2029-06-30
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.